Tamflo D 0.4mg/0.5mg Capsule PR is a formulation that combines two active ingredients designed to assist men suffering from benign prostatic hyperplasia, commonly known as an enlarged prostate. This condition often leads to various urinary difficulties, including a frequent urge to urinate or challenges in starting urination. While this medication can alleviate these symptoms, it is important to note that it does not serve as a preventive measure against prostate cancer. The capsule can be ingested with or without food; however, it is advised to take it consistently at the same time each day to ensure optimal effectiveness. Your healthcare provider will determine the appropriate dosage tailored to your needs. For the best outcomes, it is crucial not to skip any doses, even if you are feeling better, as it may take up to four weeks to observe noticeable improvements in your symptoms. If there is no enhancement in your condition after this period or if symptoms worsen, it is essential to reach out to your physician for further guidance. The common adverse effects associated with this medication include issues like impotence, reduced sexual desire, breast discomfort, and complications with ejaculation. If you experience these effects and they cause concern or do not resolve, it is advisable to contact your healthcare provider. Additionally, some patients may experience dizziness or drowsiness, especially when they first start the treatment. It is imperative to remember that the prescribing doctor has evaluated that the potential benefits of this medication outweigh the associated risks. Tamflo D is not intended for use by women or children. Prior to beginning treatment, inform your physician if you have conditions such as low blood pressure or any form of liver or kidney impairment, as this may impact your suitability for the medication.
-15%

Tamflo D 0.4mg/0.5mg PR (Tamsulosin (0.4mg) + Dutasteride (0.5mg))
Original price was: ₹316.30.₹269.90Current price is: ₹269.90.
Add to cart
Buy Now

Reviews
There are no reviews yet.